Featured on Science: Designer antibodies could battle COVID-19 before vaccines arrive

On 29 May, Lilly, working with AbCellera, launched the first human study of a monoclonal antibody—a phase I trial testing its safety and tolerability in hospitalized COVIDcampaign-pages/bispecifics/-19 patients.

Full coverage on Science.


Together we can make game-changing discoveries.